<VariationArchive RecordType="classified" VariationID="1066819" VariationName="NC_000017.10:g.(?_7571752)_(7574043_?)del" VariationType="Deletion" Accession="VCV001066819" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-07-29" DateCreated="2021-05-10" MostRecentSubmission="2023-03-26">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1054644" VariationID="1066819">
      <GeneList>
        <Gene Symbol="TP53" FullName="tumor protein p53" GeneID="7157" HGNC_ID="HGNC:11998" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7668421" stop="7687490" display_start="7668421" display_stop="7687490" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7571719" stop="7590867" display_start="7571719" display_stop="7590867" Strand="-" />
          </Location>
          <OMIM>191170</OMIM>
          <Haploinsufficiency last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000017.10:g.(?_7571752)_(7574043_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" innerStart="7571752" innerStop="7574043" display_start="7571752" display_stop="7574043" variantLength="2292" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.(?_7571752)_(7574043_?)del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.(?_7571752)_(7574043_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000017.10:g.(?_7571752)_(7574043_?)del AND Li-Fraumeni syndrome" Accession="RCV001377919" Version="2">
        <ClassifiedConditionList TraitSetID="2589">
          <ClassifiedCondition DB="MedGen" ID="C0085390">Li-Fraumeni syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-08-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2023-03-26">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21056402</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21761402</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22178617</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25794615</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26205489</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26580448</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30709875</ID>
        </Citation>
        <DescriptionHistory Dated="2023-03-24">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="2589" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10539" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome</ElementValue>
                <XRef ID="MONDO:0018875" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
                <XRef ID="428850001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sarcoma family syndrome of Li and Fraumeni</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6902" />
                <XRef ID="6902" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2019</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="C0085390" DB="MedGen" />
              <XRef ID="MONDO:0018875" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3100971" SubmissionDate="2023-03-21" DateLastUpdated="2023-03-26" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000546.5_Deletion (Exons 10-11)|MedGen:C0085390" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001575373" DateUpdated="2023-03-26" DateCreated="2021-05-10" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21056402</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21761402</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26580448</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30709875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22178617</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25794615</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26205489</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 10-11 of the TP53 gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. A similar copy number variant has been observed in individuals with clinical features of Li-Fraumeni syndrome (PMID: 21056402, 21761402, 26580448, 30709875; Invitae). This variant disrupts the C-terminal domain of the TP53 protein, which is required for DNA binding and transactivation activity (PMID: 22178617, 25794615, 26205489). While functional studies have not been performed to directly test the effect of this variant on TP53 protein function, this suggests that disruption of this region of the protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.(?_7571752)_(7574043_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085390" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12974844</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3100971" TraitType="Disease" MappingType="XRef" MappingValue="C0085390" MappingRef="MedGen">
        <MedGen CUI="C0085390" Name="Li-Fraumeni syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

